Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 941 to 950 of 2733 total matches.

Ceritinib (Zykadia) for Non-Small Cell Lung Cancer

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
-positive metastatic NSCLC; crizotinib was the first.1 Translocations of the ALK gene are found in about 5 ...
Ceritinib (Zykadia – Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). It is the second tyrosine kinase inhibitor to be approved for ALK-positive metastatic NSCLC; crizotinib was the first. Translocations of the ALK gene are found in about 5% of lung cancers; they occur predominantly in nonsmokers with adenocarcinoma.
Med Lett Drugs Ther. 2014 Jul 21;56(1447):62-3 |  Show IntroductionHide Introduction

Drugs for Hypertriglyceridemia

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013  (Issue 1411)
triglyceride levels and should be tried first.1-3 TRIGLYCERIDE LEVELS AND RISK — Mildly (150- 200 mg/dL ...
Fibrates, niacin and fish oil are promoted for treatment of hypertriglyceridemia. HMG-CoA reductase inhibitors (statins) can lower elevated serum concentrations of triglycerides, but less so than fibrates, niacins or fish oil. Lifestyle changes such as weight reduction, exercise and decreasing alcohol intake can also lower serum triglyceride levels and should be tried first.
Med Lett Drugs Ther. 2013 Mar 4;55(1411):17-9 |  Show IntroductionHide Introduction

Enlicitide (Lipfendra) – An Oral PCSK9 Inhibitor for LDL-Cholesterol Lowering

   
The Medical Letter on Drugs and Therapeutics • Aug 31, 2026  (Issue 1762)
(Leqvio) are injected subcutaneously.1 Lipfendra was approved under the Commissioner’s National Priority ...
Enlicitide (Lipfendra – Merck), an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, has been approved by the FDA to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). It is the first oral PCSK9 inhibitor to be approved in the US; the other FDA-approved PCSK9 inhibitors (alirocumab [Praluent], evolocumab [Repatha], and lerodalcibep [Lerochol]) and the PCSK9-directed small interfering RNA inclisiran (Leqvio) are injected subcutaneously. Lipfendra was approved under...
Med Lett Drugs Ther. 2026 Aug 31;68(1762):137-9   doi:10.58347/tml.2026.1762a |  Show IntroductionHide Introduction

Chemotherapy for Esophageal, Gastric and Colorectal Cancers

   
Treatment Guidelines from The Medical Letter • Aug 01, 2006  (Issue 48)
is similar to that with surgery alone. 1 Prospective clinical trials have found that chemotherapy, usually ...
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
Treat Guidel Med Lett. 2006 Aug;4(48):55-60 |  Show IntroductionHide Introduction

IV Meloxicam (Anjeso) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
in efficacy and safety to other NSAIDs.1 It has COX-2 selectivity in vitro, which decreases at higher ...
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):100-2 |  Show IntroductionHide Introduction

Rezafungin (Rezzayo) for Invasive Candida Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
, 33% to amphotericin B, and 1% to echinocandins.1 STANDARD TREATMENT ― In patients with candidemia ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for once-weekly treatment of candidemia and invasive candidiasis (IC) in adults with limited or no alternative options. It is the first new drug to become available in the US in more than 15 years for treatment of systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4   doi:10.58347/tml.2024.1705d |  Show IntroductionHide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
, irritability/hyperactivity, fever, sweating and aspiration pneumonitis. 1 Gastric lavage through a large ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 |  Show IntroductionHide Introduction

In Brief: Phentermine (Lomaira) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016  (Issue 1509)
with topiramate for years.1 Table 1. Phentermine Products Usual Drug Formulations Dosage Cost1 Phentermine2 ...
The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only approved for short-term use (a few weeks) in adults with a body mass index (BMI) ≥30 kg/m2, or with a BMI ≥27 kg/m2 in addition to a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes. Phentermine has been available alone and in combination with topiramate for years.1Lomaira was approved by the FDA under an abbreviated new drug application (ANDA) and is...
Med Lett Drugs Ther. 2016 Dec 5;58(1509):158 |  Show IntroductionHide Introduction

COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
(Pfizer) or 6 years old (Moderna).1 The bivalent Pfizer vaccine had previously been authorized for use ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e1 |  Show IntroductionHide Introduction

In Brief: Oral Minoxidil for Hair Loss

   
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022  (Issue 1666)
IN BRIEF Oral Minoxidil for Hair Loss 1. A Adil and M Godwin. The effectiveness of treatments ...
Topical minoxidil (Rogaine, and others), which is available over the counter, has been used for treatment of hair loss in men and women for more than 30 years. Recently published trials suggest that off-label use of a low dose of oral minoxidil may also be effective.
Med Lett Drugs Ther. 2022 Dec 26;64(1666):208 |  Show IntroductionHide Introduction